Artikelen door HollandBIO

Shire and Takeda come to terms with a $64B deal

We have a deal—a preliminary one, at least. Late Tuesday, after a fifth buyout offer from Takeda, Shire said the Japanese drugmaker had finally landed on a proposal worth recommending to shareholders. It’s a cash-and-stock bid now worth $64 billion or so, about $4 billion more than its first offer. The deal still has to […]

MDxHealth: SelectMDx Included in Dutch DRG Reimbursement System

MDxHealth SA, a world leader in molecular diagnostics for urological cancers, announced the inclusion of SelectMDx for Prostate Cancer, its non-invasive ‘liquid biopsy’ test that helps to identify patients at increased risk of having aggressive prostate cancer, in the Dutch Diagnosis Related Groups (DRG) reimbursement system. The DRG reimbursement system was introduced in the Netherlands […]

Biogen and Ionis Expand Strategic Collaboration

Biogen and Ionis Pharmaceuticals announced that they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases. This collaboration capitalizes on Biogen’s expertise in neuroscience research and drug development and Ionis’ leadership in RNA targeted therapies with the goal of developing […]

,

Big Data, Big Produce

In the last few decades, with the introduction of GMOs, the agricultural industry was turned upside down. Major consolidations between companies took place, while sustainability and big data have become ever more important. BioVox had a conversation on the most important trends within the agri-biotech sector with Johan Cardoen, Managing Director of VIB, and with […]

, ,

Adviesrapport Sneller, Beter en Goedkoper slaat de plank mis

Vandaag publiceerde de Raad voor Volksgezondheid en Samenleving (RVS) haar adviesrapport “Ontwikkeling nieuwe geneesmiddelen: Beter, sneller, goedkoper”. HollandBIO heeft reikhalzend uitgekeken naar het rapport. In de totaal gepolariseerde discussie rondom geneesmiddelenprijzen, legde de adviesvraag die ten grondslag aan het rapport lag namelijk de vinger op de zere plek. Want hoewel biotech haar belofte waarmaakt en […]